These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8821646)

  • 1. Induction of antibodies against structural proteins of hepatitis C virus in mice using recombinant adenovirus.
    Makimura M; Miyake S; Akino N; Takamori K; Matsuura Y; Miyamura T; Saito I
    Vaccine; 1996 Jan; 14(1):28-36. PubMed ID: 8821646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus.
    Arribillaga L; de Cerio AL; Sarobe P; Casares N; Gorraiz M; Vales A; Bruna-Romero O; Borrás-Cuesta F; Paranhos-Baccala G; Prieto J; Ruiz J; Lasarte JJ
    Vaccine; 2002 Dec; 21(3-4):202-10. PubMed ID: 12450695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of the E1E2 proteins of hepatitis C virus expressed by recombinant adenoviruses.
    Seong YR; Choi S; Lim JS; Lee CH; Lee CK; Im DS
    Vaccine; 2001 Apr; 19(20-22):2955-64. PubMed ID: 11282207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic immunization of wild-type and hepatitis C virus transgenic mice reveals a hierarchy of cellular immune response and tolerance induction against hepatitis C virus structural proteins.
    Satoi J; Murata K; Lechmann M; Manickan E; Zhang Z; Wedemeyer H; Rehermann B; Liang TJ
    J Virol; 2001 Dec; 75(24):12121-7. PubMed ID: 11711603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterologous Immunity between Adenoviruses and Hepatitis C Virus: A New Paradigm in HCV Immunity and Vaccines.
    Singh S; Vedi S; Samrat SK; Li W; Kumar R; Agrawal B
    PLoS One; 2016; 11(1):e0146404. PubMed ID: 26751211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of Hepatitis C Virus Core and E2 antigenic recombinant proteins and their use for development of diagnostic assays.
    Ali A; Nisar M; Idrees M; Rafique S; Iqbal M
    Int J Infect Dis; 2015 May; 34():84-9. PubMed ID: 25796431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
    Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral immunization with attenuated Salmonella carrying a co-expression plasmid encoding the core and E2 proteins of hepatitis C virus capable of inducing cellular immune responses and neutralizing antibodies in mice.
    Cao J; Chen Z; Ren Y; Luo Y; Cao M; Lu W; Zhao P; Qi Z
    Vaccine; 2011 May; 29(20):3714-23. PubMed ID: 21396407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel adeno‑associated virus‑based genetic vaccines encoding hepatitis C virus E2 glycoprotein elicit humoral immune responses in mice.
    Zhu F; Wang Y; Xu Z; Qu H; Zhang H; Niu L; Xue H; Jing D; He H
    Mol Med Rep; 2019 Feb; 19(2):1016-1023. PubMed ID: 30569131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of noncovalent hepatitis C virus envelope E1-E2 complexes is not required for the induction of antibodies with neutralizing properties following DNA immunization.
    Fournillier A; Depla E; Karayiannis P; Vidalin O; Maertens G; Trépo C; Inchauspé G
    J Virol; 1999 Sep; 73(9):7497-504. PubMed ID: 10438839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of route of delivery on heterologous protection against HCV induced by an adenovirus vector carrying HCV structural genes.
    Guan J; Wen B; Deng Y; Zhang K; Chen H; Wu X; Ruan L; Tan W
    Virol J; 2011 Nov; 8():506. PubMed ID: 22054309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vector.
    Ezelle HJ; Markovic D; Barber GN
    J Virol; 2002 Dec; 76(23):12325-34. PubMed ID: 12414973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of conventional or replicating nucleic acid-based vaccines and recombinant Semliki forest virus-derived particles for the induction of immune responses against hepatitis C virus core and E2 antigens.
    Vidalin O; Fournillier A; Renard N; Chen M; Depla E; Boucreux D; Brinster C; Baumert T; Nakano I; Fukuda Y; Liljeström P; Trépo C; Inchauspé G
    Virology; 2000 Oct; 276(2):259-70. PubMed ID: 11040118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of hepatitis C virus-specific cytotoxic T lymphocytes in mice by an intrahepatic inoculation with an expression plasmid.
    Kamei A; Tamaki S; Taniyama H; Takamura S; Nishimura Y; Kagawa Y; Uno-Furuta S; Kaito M; Kim G; Toda M; Matsuura Y; Miyamura T; Adachi Y; Yasutomi Y
    Virology; 2000 Jul; 273(1):120-6. PubMed ID: 10891414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered Glycosylation Patterns Increase Immunogenicity of a Subunit Hepatitis C Virus Vaccine, Inducing Neutralizing Antibodies Which Confer Protection in Mice.
    Li D; von Schaewen M; Wang X; Tao W; Zhang Y; Li L; Heller B; Hrebikova G; Deng Q; Ploss A; Zhong J; Huang Z
    J Virol; 2016 Dec; 90(23):10486-10498. PubMed ID: 27630242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Experimental study of immunization of mice with hepatitis C virus genetic vaccine constructs].
    Dou J; Liu K; Chen Z; Wo J; Liu Y; Xu C; Chen M; Jin J; He N
    Zhonghua Nei Ke Za Zhi; 1999 Jun; 38(6):390-2. PubMed ID: 11798674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of immunization in mice with recombinant DNA encoding the hepatitis C virus structural protein.
    Dou J; Liu K; Chen Z; Wo J; He N; Liu Y; Zhang M; Wang X; Xu C
    Chin Med J (Engl); 1999 Nov; 112(11):1036-9. PubMed ID: 11721468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines.
    Siler CA; McGettigan JP; Dietzschold B; Herrine SK; Dubuisson J; Pomerantz RJ; Schnell MJ
    Virology; 2002 Jan; 292(1):24-34. PubMed ID: 11878905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ratio of HCV structural antigens in protein-based vaccine formulations is critical for functional immune response induction.
    Martínez-Donato G; Musacchio A; Alvarez-Lajonchere L; Acosta-Rivero N; Amador Y; Guerra I; Peña D; Pérez A; Castro J; Puentes P; Soria Y; Cosme K; Sanchez J; Dueñas-Carrera S
    Biotechnol Appl Biochem; 2010 Jul; 56(3):111-8. PubMed ID: 20515441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA vaccination for the induction of immune responses against hepatitis C virus proteins.
    Inchauspé G; Major ME; Nakano I; Vitvitski L; Trépo C
    Vaccine; 1997 Jun; 15(8):853-6. PubMed ID: 9234532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.